Introduction
The differential diagnosis of leukoencephalopathy is extensive [1, 2] . Specialized investigations, such as biochemical, genetic or neuropathologic analyses, are required for an accurate diagnosis. Due to recent advances in molecular genetics, genetic tests play an important role in the diagnosis of some leukoencephalopathies [1] . To perform genetic tests efficiently, it is important to understand the characteristic clinical features of a disease and to establish useful diagnostic criteria.
Since the discovery of colony-stimulating factor 1 receptor (CSF1R) as a causative gene for hereditary diffuse leukoencephalopathy with spheroids (HDLS) [3] , and more recently for pigmented orthochromatic leukodystrophy [4] , more than 120 cases with CSF1R mutations have been reported worldwide but it has been relatively more common in Japan compared with other countries [5] . HDLS and pigmented orthochromatic leukodystrophy cases, carriers of CSF1R mutations, are characterized as having 'adult-onset leukoencephalopathy with axonal spheroids and pigmented glia' (ALSP) [4] . Interestingly, CSF1R mutations are not always found in pathologically-confirmed HDLS cases [6] . Mutations in other genes appear to be responsible in cases of HDLS that are negative for CSF1R mutations. Indeed, mutations in alanyl-transfer RNA synthetase 2 (AARS2) have been recently identified in five cases who were suspected to have ALSP, but were negative for CSF1R mutation [7] .
Recently, we have clarified the clinical characteristics of ALSP by analyzing 122 cases with CSF1R mutations [5] . Based on these findings, we proposed diagnostic criteria for ALSP due to CSF1R mutation and attempted to validate them.
Methods

Establishing diagnostic criteria
To establish diagnostic criteria, a working group was organized, consisting of board-certified neurologists from five institutions (Mayo Clinic, Niigata University, Shinshu University School of Medicine, Kyoto Prefectural University of Medicine and Tokushima University Graduate School) who had observed patients with ALSP. The diagnostic criteria were created based on the clinical characteristics obtained from our case series and review of the literature and further discussions among the study working group [5] . We defined five core diagnostic features (Table 1) . Three exclusionary findings were added to increase diagnostic specificity. Patients who had three of the five core features (Table 1, criteria 2, 3 and 4a) and had a CSF1R mutation were classified as definitely having ALSP ('definite'). Patients who did not have results from genetic testing were identified as having 'probable' or 'possible' ALSP. The 'probable' criteria also required that the patients had all five core features identified in Table 1 , but the 'possible' criteria required that only three were fulfilled (criteria 2a, 3 and 4a), with the aim of preventing false-negative diagnoses and missed opportunities for the genetic testing of those who lacked typical clinical features. Although not directly used to determine the diagnosis, we added four supportive findings to assist clinicians in making a diagnosis. Figure 1 shows the characteristic brain computed tomography/magnetic resonance imaging (MRI) findings of ALSP and Table 2 provides additional comments on the diagnostic criteria. 
Validation of the diagnostic criteria
We used CSF1R mutation-positive cases to determine the sensitivity of our criteria. First, we applied the criteria to 26 ALSP cases who were seen by us and 96 cases previously identified in the literature [5] . Next, we applied them to 67 cases with CSF1R mutationnegative leukoencephalopathies to test the specificity of the criteria. These cases were suspected to have ALSP with at least white matter abnormalities on brain MRI and were referred to our institutions for genetic test for CSF1R mutation. The primary causes of the mutation-negative leukoencephalopathies were unknown. We also applied the criteria to 40 cases with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADA-SIL) who had NOTCH3 mutations, because CADASIL is one of the main differential diseases of ALSP [3] . Cases diagnosed as 'probable' met all five core features. However, in this retrospective study, the exclusion of other diseases, one of the core features, was not always taken into account because we could not determine whether sufficient assessment for a differential diagnosis had been conducted in every case. All genetic analyses were approved by the institutional review board of each of the five institutions listed above. Informed consent was obtained from all of the participants.
Results
Among the ALSP cases with CSF1R mutations, two of 26 cases in our cohort and 37 of 96 cases from the literature were excluded due to a lack of information, including insufficient brain imaging or hereditary data. The number of cases fulfilling each designation is shown in Table 3 . If we calculated the diagnostic sensitivity as a ratio of the number of cases diagnosed as 'probable' or 'possible' to the total number of cases, the sensitivity was 96% for our cohort and 99% when combined with the literature review cases. Fourteen of 67 cases with mutation-negative leukoencephalopathies and eight of 40 CADASIL cases were excluded due to missing information necessary for our evaluation. For diagnostic specificity, 22 (42%) and 28 (88%) cases did not meet either the 'probable' or 'possible' criteria, respectively (Table 3) .
Discussion
In the process of establishing diagnostic criteria, we placed a greater weight on sensitivity than specificity because a substantial number of cases with ALSP are underdiagnosed. This retrospective validation of these diagnostic criteria showed that they had high sensitivity (≥96%). There was almost no possibility that cases with ALSP were missed when we used these criteria. We had only one ALSP case who did not fit the criteria [8] . This case initially presented with gait abnormalities and was cognitively normal in the early stages of disease when the criteria were applied. However, cognitive impairment subsequently appeared and the patient was classified as 'probable' at that time. Although cognitive impairment is inevitable in ALSP, it should be noted that it can be inconspicuous during the initial disease stages.
Thinning of the corpus callosum is characteristic of ALSP [9] and, thus, we included it in a parameter of 'probable.' Of the 29 cases from the literature that fulfilled the 'possible' criteria, information about the corpus callosum was not obtained in 17 cases. It is estimated that more cases would have been diagnosed as 'probable' if their corpus callosum had been evaluated. A majority of cases with mutation-negative leukoencephalopathy were diagnosed as 'possible,' but four cases met the 'probable' criteria, suggesting that the thinning of the corpus callosum is characteristic, but is not specific to ALSP. We assumed that brain calcifications have high sensitivity and specific diagnostic power [10, 11] . However, we could not sufficiently validate this finding due to insufficient information in the literature. Thus, we did not include it in the core features, but in the supportive findings.
When the criteria were applied to the cases who had CSF1R mutation-negative leukoencephalopathies On brain MRI scans, the white matter lesions without gadolinium enhancement can be scattered and asymmetric during the initial stages of the disease but later become confluent, diffuse and more symmetric. Frontal and parietal lobe predominance is observed with involvement of the periventricular deep white matter and dilation of the lateral ventricles. Thinning of the corpus callosum with signal abnormalities is observed even in the early stages of the disease [9, 11] . Fluid-attenuated inversion recovery sagittal imaging is recommended to evaluate changes in the corpus callosum. Abnormal signaling in the pyramidal tracts and diffusion-restricted lesions are observed in some cases [5, 11] . None of the ALSP cases showed middle cerebellar peduncle lesions, which are known as a characteristic finding of some leukoencephalopathies On brain CT scans, calcifications are often observed bilaterally in the frontal white matter adjacent to the anterior horn of the lateral ventricle and the subcortical region of the parietal lobe. Calcifications can be very small. Thus, thin-slice CT (1 mm) is recommended to detect them [5, 11] . Characteristic 'stepping stone appearance' can be seen on sagittal view [10] 
Neuropathologic findings
Neuropathologic findings include prominent white matter lesions with myelin and axon damages, neuroaxonal swelling (spheroid formation) and pigmented macrophage and glia [4] 6. CSF1R mutation All reported mutations were located within the tyrosine kinase domain of CSF1R except for two frameshift mutations [5] ALSP, adult-onset leukoencephalopathy with axonal spheroids and pigmented glia; CSF1R, colony-stimulating factor 1 receptor; CT, computed tomography; MRI, magnetic resonance imaging.
or CADASIL with NOTCH3 mutations, the specificity was 42% and 88%, respectively. We considered that the relatively low specificity for mutation-negative leukoencephalopathies was due to the minimum requirements set for the 'possible' designation, which were in place to avoid missing atypical cases of ALSP.
To yield higher specificity, the brain imaging characteristics listed in Table 2 , including the distribution pattern of the white matter lesions and the brain calcifications, may be beneficial. However, these criteria could successfully be used to differentiate CADASIL from ALSP. Cerebral infarction cases frequently present with diffusion-restricted lesions on brain MRI that are occasionally also observed in ALSP cases (Fig. 1e) . Therefore, hereditary cerebral small vessel diseases, including CADASIL, are part of the differential diagnoses of ALSP. One of the exclusion criteria, 'stroke-like episodes more than twice,' was helpful for excluding CADASIL because there were no ALSP cases who had two or more stroke-like episodes. Additional useful points for differentiating ALSP from other leukoencephalopathies are shown in Table S1 . Patients with leukoencephalopathy due to AARS2 mutations, termed as AARS2-L [12] , develop similar clinical and radiologic features to those with ALSP. However, some differentiating points were present in the cases with AARS2-L, e.g. autosomal recessive pattern of inheritance, relatively younger age at onset including childhood onset and presence of ovarian failure in all female cases [7, 12, 13] . On brain MRI, white matter rarefaction, tract involvement, spared middle section of the brain and cerebellar atrophy seemed to be more frequently observed in cases with AARS2 mutation [13] . Brain calcifications observed in ALSP have not been seen in patients with AARS2-L [12] . Only one biopsied case showed pathologic findings similar to ALSP [7] , whereas another biopsied case failed to provide any specific findings [14] . Thus, the pathologic characteristics of AARS2-L remain unclear. Notably, mutations in AARS2 can also cause infantile mitochondrial cardiomyopathy [15] . Therefore, further studies would be warranted to determine clinical, radiologic and even pathologic similarities and differences between ALSP and AARS2-L.
This study had the following limitations. First, we retrospectively extracted the clinical data and, thus, there may be variations or bias in the volume of information depending on the medical records or literature. In particular, the disease duration at the time of applying the criteria varied among the cases (we could not calculate the mean disease duration due to insufficient data). If the criteria were applied to patients with the very early stage of the illness, the sensitivity would become lower. Secondly, except for cases with CADA-SIL, we could not validate these criteria with cases with other specific leukoencephalopathies. To clarify the differential points among leukoencephalopathies, it would be preferable to establish diagnostic criteria for other leukoencephalopathies and to assess the utility of these criteria for each disease.
Comprehensive genetic testing using the panel or exome sequence analyses has become technically available and has facilitated genetic diagnosis of adultonset leukoencephalopathies. Although panel testing for these genetic disorders is becoming more popular, its application to clinical practice may be limited due to its cost and availability. Accurate clinical suspicion will facilitate gene testing of the target gene, and eventually reduce the cost and time of the diagnostic process. We believe that these criteria are useful for the clinical diagnosis of ALSP. However, the criteria should be validated in larger prospective cohorts and further refined, especially for achieving higher specificity. Sensitivity was calculated as a ratio of the number of cases who were diagnosed as probable or possible to the total number of cases. 
